English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/134058
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorMontero, Juan Carlos-
dc.contributor.authorEsparís-Ogando, Azucena-
dc.contributor.authorRe-Louhau, M. F.-
dc.contributor.authorSeoane, Samuel-
dc.contributor.authorAbad, María del Mar-
dc.contributor.authorCalero, R.-
dc.contributor.authorOcaña, Alberto-
dc.contributor.authorPandiella, Atanasio-
dc.date.accessioned2016-06-24T10:59:09Z-
dc.date.available2016-06-24T10:59:09Z-
dc.date.issued2012-
dc.identifierdoi: 10.1038/onc.2012.572-
dc.identifierissn: 0950-9232-
dc.identifiere-issn: 1476-5594-
dc.identifier.citationOncogene 33(2): 148-156 (2012)-
dc.identifier.urihttp://hdl.handle.net/10261/134058-
dc.description.abstractTriple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite response to chemotherapy, relapses are frequent and resistance to available treatments is often seen in the metastatic setting. Therefore, identification of new therapeutic targets is required. With this aim, we have profiled the activation status of 44 receptor tyrosine kinases (RTKs) and their major signaling pathways in patient-derived TNBC tumors. Frequent co-activation of several RTKs as well as the extracellular signal-regulated protein kinases 1 and 2 (Erk1/2) and mammalian target of rapamycin (mTOR) routes was found. Pharmacologic targeting of the activated kinases indicated that agents that attack the mTOR route are more potent and efficient antitumoral treatments than agents targeting RTKs. mTOR signals through two multiprotein complexes, mTORC1 and mTORC2. We used a genetic approach to explore the contribution of each of the two mTOR branches to the regulation of cell number of TNBC cells. RNA interference experiments indicated that mTORC1 predominated over mTORC2 in the control of TNBC cell proliferation. Moreover, RNA interference of mTOR had a superior antiproliferative action than separately acting on mTORC1 or mTORC2. To analyze the relevance of mTOR targeting in vivo, we used mice with TNBC. Treatment of these mice with BEZ235, a drug that targets mTOR, slowed tumor growth. Mechanistically, BEZ235 delayed cell cycle progression without affecting cell viability. Our results show that TNBCs are particularly sensitive to inhibition of the mTOR pathway, and indicate that mTOR targeting may be a more efficient anti-TNBC therapy than exclusively acting on the mTORC1 branch of the pathway. This is relevant as most mTOR inhibitors used in the clinic act on mTORC1. Collectively with the fact that BEZ235 synergized with drugs commonly used in the treatment of TNBC, our data support the clinical development of agents that act on mTOR as a therapy for this disease.-
dc.description.sponsorshipThis work was supported by grants from the Ministry of Science and Innovation of Spain (BFU2009–07728/BMC to AP, and PS09/00868 to AE-O). JCM and SS were supported by the Cancer Center Network Program from the ISCIII (RD06/0020/0041). The Cancer Research Institute, and the work carried out at AP and AE-O laboratories, receive support from the European Community through the regional development funding program (FEDER), and from the Fundación Ramón Areces. AO receives research support from the FISCAM (Grant PI2010/017) and from the ISCIII (Grant PS09/02144). -
dc.publisherNature Publishing Group-
dc.rightsclosedAccess-
dc.subjectmTOR-
dc.subjectTriple-negative breast cancer-
dc.subjectPI3K-
dc.titleActive kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer-
dc.typeartículo-
dc.identifier.doi10.1038/onc.2012.572-
dc.date.updated2016-06-24T10:59:09Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.contributor.funderMinisterio de Ciencia e Innovación (España)-
dc.contributor.funderFundación Ramón Areces-
dc.contributor.funderJunta de Comunidades de Castilla-La Mancha-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderRed Temática de Investigación Cooperativa en Cáncer (España)-
dc.contributor.funderEuropean Commission-
dc.relation.csic-
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004837es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/100008054es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.